Stronger Sell Today MTNB ranks #3150 as SELL CANDIDATE #3150 Weaker Sell

MTNB stock forecast Matinas Biopharma Holdings Inc

MTNB stock forecast

Thursday May 23, 2019 Change -1.01% Price $0.98
Chart period: 2019-02-25 - 2019-05-23




Will MTNB stock price go up or down on Fri, 24 May 2019?


Matinas Biopharma Holdings Inc Forecast and Stock Analysis

Technical MTNB stock analysis for Thursday May 23, 2019.

Sell candidate since 2019-05-22 Loss -1.01%
Shorts 4.82% ( 2019-04-15 )
Insider % n/a
Institutional % 15.00%
Beta 0.90
ROA -49.30%
Price to book USD 4.25
P/E Ratio -6.71
Next Earnings Date 2019-08-08

Matinas Biopharma Holdings Inc fell by -1.01% in the last day ( Thursday, 23rd May 2019 ) from $0.99 to $0.98 and has now fallen 3 days in a row. During day the stock fluctuated 5.26% from a day low at $0.95 to a day high of $1.00. The price has risen in 6 of the last 10 days and is up by 1.03% over the past 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -99 135 shares and in total 512 138 shares bought and sold for approximately $501 895.00.

Quick summary:

  • 30 day high of the MTNB stock price was $1.12 and low was $0.88.
  • 90 day high was $1.50 and low was $0.88.
  • 52 week high for the Matinas Biopharma Holdings Inc - $1.50 and low - $0.32.


Matinas Biopharma Holdings Inc lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -26.53% during the next 3 months and, with 90% probability hold a price between $0.62 and $0.77 at the end of this period.

Click here for today's Top 5 Trending Companies


Some negative signals were issued as well, and these may have some influence on the near short-term development. Matinas Biopharma Holdings Inc holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $1.02. On a fall, the stock will find some support from the short-term average at $0.97. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. A sales signal was issued from a pivot top point on Tuesday May 21, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 36 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Matinas Biopharma Holdings Inc finds support from accumulated volume at $0.98.

Support: $0.98 Price: $0.98 Resistance: $0.99


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.05 between high and low, or 5.26%. For the last week the stock has had a daily average volatility of 5.47%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

5.47 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Stronger Sell Today MTNB ranks #3150 as SELL CANDIDATE #3150 Weaker Sell
MTNB $0.98 ($-0.01 -1.01%)
MTNB is down $0.01 today, but where's it headed in 2019?
Zacks Investment Research is releasing its prediction for MTNB based on the 1-3 month system that more than doubles the S&P 500.

This report is free today for readers.

Click here – the MTNB analysis is free »

Will MTNB stock price go up or down
on Fri, 24 May 2019?


Proudly made at

Rise Vilnius
in partnership with
Barclays Bank